Navigation Links
NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011
Date:10/4/2011

tage clinical trials," Ms. Powers continued.  "In the trials so far, patients who received the DCVax® dendritic cell treatments lived for years longer than patients receiving standard of care (not just weeks or months longer), and without toxicity.  Building upon the original discovery of dendritic cells by Dr. Steinman, we are working to make dendritic cell treatments widely available for patients, and believe that such treatments have the potential to become a new standard of care for most cancers."

The Company's broad platform technology for dendritic cell-based vaccines is currently being tested in an ongoing 240-patient Phase II clinical trial for newly diagnosed Glioblastoma multiforme ("GBM") -- the most aggressive and lethal form of brain cancer.  The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in multiple other cancers.  The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.

Dr. Maida joined the Company in June, 2011, as Chief Operating Officer ("COO"), bringing more than 20 years' experience in building oncology companies, with expertise in the business, financial, clinical and regulatory aspects of oncology products, as well as the underlying science.  Over these two decades, Dr. Maida has held positions as Chairman, CEO, COO, CSO, CFO and VP Business Development, and has raised nearly $200 million in financings for oncology companies.  Among these experiences, he served as CEO of CancerVax, an early leader in cancer vaccines.  In that role, he raised the company's first $30 million of funding, and was responsible for conducting multi-hundred patient, multi-center clinical trials with the company's cancer vaccines.  Prior to joining NORTHWEST BIO, Dr. Maida was serving as Global Head of Oncology for a leading contract research organiz
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe
2. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
3. Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner
4. Northwest Biotherapeutics Announces Change and Expansion of Management Team
5. Northwest Biotherapeutics Announces Series of Financing Arrangements
6. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
7. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
8. Northwest Biotherapeutics Addresses Recent Market Activity
9. Cell Therapeutics, Inc. (CTI) to Present at Life Science Innovation Northwest
10. Registration Open for WBBAs Life Science Innovation Northwest 2011 Event Webcast
11. BioSpace Highlights the Northwests Growing Life Science Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Massachusetts og SHENZHEN ... Tech Solutions Co., LTD, (BGI Tech), et datterselskab ... lancering af en ny human whole exome-sekvenseringstjeneste baseret ... Complete Genomics, højt anset i branchen for at ... højfølsom registrering af alle typer varianter, blev købt ...
(Date:7/22/2014)... Switzerland (PRWEB) July 22, 2014 ... are becoming an increasingly common sight. The rapid ... they are now well- established as a core ... low maintenance has made them the gas analyzer ... locations and conditions encountered in some processes have ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Holomic ... with the debut of its fluorescent immunoassay reader, ... Chemistry (AACC) meeting in Chicago, July 28-31, 2014. ... top versions, the HRDR-300 is a highly sensitive, ... to analyze fluorescent lateral flow immunoassays with high ...
(Date:7/21/2014)... 21, 2014 Lawrence Livermore ... Board (WIB) and Las Positas College (LPC) recently ... education and hands-on training for veterans, officials recently ... at Las Positas is designed to help ... engineering technician careers, and establishes a pipeline of ...
Breaking Biology Technology:BGI Tech lancerer Human Whole Exome-sekvenseringstjeneste på Complete Genomics avancerede platform 2METTLER TOLEDO Shows How Tunable Diode Lasers (TDLs) Can Be Installed Where No TDLs Have Gone Before 2Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2Engineering Program Established for Veterans 2Engineering Program Established for Veterans 3
... EUREKA Cluster dedicated to Smart Systems Integration, will be ... community on 14-17 June 2011 in Helsinki, Finland. The ... the creation of new consortia and new projects by ... discuss proposals. EURIPIDES, in close cooperation with VTT and ...
... 20, 2011 Harvest Technologies Corp. ( www.harvesttech.com ) ... sixty patient Heart Failure trial have been enrolled at ... trial is intended to evaluate the safety and clinical ... patients with Congestive Heart Failure (CHF) when using a ...
... full year as a public company, 2010, the biotechnology developer Divine ... and grew Q4 revenue by 88 percent over the previous Q4, ... $5.4 million, up by $1.9 million over the previous year. Fourth-quarter ... quarter of 2009. The maker of topical treatments for ...
Cached Biology Technology:Harvest Technologies Announces Initial Enrollment in Its REVIVE-1 Trial (REtrograde Vascular Infusion of BMAC to ImproVe Heart FailurE) 2Divine Skin Posts Record Sales for 2010: Up 55% Over 2009 2Divine Skin Posts Record Sales for 2010: Up 55% Over 2009 3
(Date:7/22/2014)... 14, 2014, by lightning from a weather system that moved ... fires: Stokes Fire, Gold Hikes Fire, French Creek Fire and ... now one larger fire. The fires are burning in timber ... acres in size. The present fire situation continues to ... firefighter safety is the priority on the Carlton Complex fires. ...
(Date:7/22/2014)... for Health Policy and Economics have linked tighter ... rates for schizophrenic individuals. , The study comes ... health actually save money, when other costs are ... an extra approval step before tests or treatments ... called prior authorization is intended to encourage ...
(Date:7/22/2014)... research team from the National Institute of Standards ... has demonstrated a dramatically improved technique for analyzing ... vibration "signatures." The new NIST technique is an ... spectroscopy, but one that delivers signals that are ... scattering, and 100 times stronger than obtained from ...
Breaking Biology News(10 mins):Are state Medicaid policies sentencing people with mental illnesses to prison? 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3
... (RFRH) systems with mulches were first researched in the ... water availability and to increase crop production. In RFRH ... bare or mulched furrows serve as planting zones. The ... in many parts of the world as a means ...
... of 34 institutions in 15 countries contributing to the measurements ... network, InGOS. , The network focuses on providing accurate information ... for a more vigorous climate action. In order to ... of greenhouse gas emissions is essential and not only ...
... article in the New England Journal of Medicine ... B was able to convert severe hemophilia to moderate or ... Methods Editor for Human Gene Therapy and ... represents an important milestone and "demonstrates unequivocally that gene therapy ...
Cached Biology News:Improved rainwater harvesting system promising 2DTU is participating in a European network on measurement of greenhouse gases 2Commentary and podcast on landmark gene therapy clinical trial for hemophilia B 2